Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cyclin-dependent kinase 9 (CDK9), a member of the cyclin-dependent protein kinase (CDK) family, is involved in transcriptional elongation of several target genes. CDK9 is ubiquitously expressed and has been shown to contribute to a variety of malignancies such as pancreatic, prostate and breast cancers. Here we report the development of a heterobifunctional small molecule proteolysis targeting chimera (PROTAC) capable of cereblon (CRBN) mediated proteasomal degradation of CDK9. In HCT116 cells, it selectively degrades CDK9 while sparing other CDK family members. This is the first example of a PROTAC that selectively degrades CDK9.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555382 | PMC |
| http://dx.doi.org/10.1039/c7cc03879h | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CREPT promotes LUAD progression by enhancing the CDK9 and RNAPII assembly to promote ERK-driven gene transcription.
Theranostics
August 2025
State Key Laboratory of Membrane Biology, School of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, 100084, China.
Despite advancements in EGFR- and KRAS-targeted therapies for lung adenocarcinoma (LUAD), novel targets are needed for patients unresponsive or resistant to current treatments. This study demonstrates the critical role of CREPT in modulating ERK-downstream gene transcription in LUAD progression. CREPT expression and function were investigated using human LUAD tissues, EGFR/KRAS mutant LUAD cell lines, and mouse models.
View Article and Find Full Text PDFA CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongation.
Mol Cell
September 2025
The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3052, Australia; Peter MacCallum Cancer Centre, Laboratory Research Division, Parkville, VIC 3052, Australia. Electronic address:
Controlled gene expression is achieved through the intricate regulation of RNA polymerase II (Pol II) progression through transcription-cycle checkpoints. While the contribution of CDK9 for Pol II pause-release is well established, the requirement for other cyclin-dependent kinases (CDKs) has not been fully elucidated. In this study, we propose a critical role for CDK11 in the Pol II pausing-to-elongation transition at a checkpoint that precedes and is independent from CDK9.
View Article and Find Full Text PDFComprehensive analysis of cholesterol metabolism-related genes in prostate cancer: integrated analysis of single-cell and bulk RNA sequencing.
Discov Oncol
July 2025
Department of Urology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Cholesterol metabolism plays a significant role in cancer progression, including prostate adenocarcinoma (PRAD), making it a promising target for therapeutic intervention. This study aimed to construct and validate a cholesterol metabolism gene (CMG)-related prognostic signature to predict prognosis in PRAD patients, while exploring its biological, clinical, and therapeutic implications.
Methods: CMGs were retrieved through comprehensive searches in public databases.
Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation.
Cancers (Basel)
July 2025
Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL 32224, USA.
CLL is the most prevalent adult leukemia in Western countries, characterized by the accumulation of monoclonal B lymphocytes. Over the past decade, the therapeutic landscape for CLL has undergone significant transformations, primarily due to the introduction of targeted small molecular therapies like BTK inhibitors and BCL-2 inhibitors, that have improved patient outcomes drastically. Despite significant advances, long-term disease management remains challenging for patients with double-refractory CLL, where responses with subsequent therapies are short-lived.
View Article and Find Full Text PDFAdvances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress.
Redox Biol
September 2025
Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address:
Kelch-like ECH-associated protein 1 (KEAP1) functions as a substrate adaptor for the Cullin 3-RING E3 ligase complex, mediating the ubiquitination and subsequent proteasomal degradation of nuclear factor erythroid 2-related factor 2 (NRF2). This regulatory mechanism maintains cellular redox homeostasis by preventing NRF2 overactivation. Proteolysis-targeting chimeras (PROTACs) have emerged as a novel therapeutic strategy that harnesses the ubiquitin-proteasome system for targeted protein degradation.
View Article and Find Full Text PDF